SAC Capital

SAC Capital initiates coverage on Livingstone Health with 'hold' call - THE EDGE SINGAPORE

Broker's Calls

SAC Capital initiates coverage on Livingstone Health with 'hold' call

The group was listed on the Singapore Exchange (SGX) via a reverse takeover in 2021.

Broker's Calls

SAC Capital downgrades GKE with reduced target price of 12.3 cents

GKE's 1HFY2022 earnings missed expectations
SAC Capital initiates coverage on Marco Polo Marine with 'buy' call at 3.2 cent price target - THE EDGE SINGAPORE

Broker's Calls

SAC Capital initiates coverage on Marco Polo Marine with 'buy' call at 3.2 cent price target

The 3.2 cent target is pegged to 8.0x FY2022 EV/EBITDA

Capital markets

Beng Kuang Marine raises $3.35 million via placement at 9 cents per share

A total of 37.2 million new shares have been placed out.
Roxy-Pacific's privatisation offer catches the eye of SAC Capital - THE EDGE SINGAPORE

Broker's Calls

Roxy-Pacific's privatisation offer catches the eye of SAC Capital

SAC Capital analyst Tracy Lim believes that Roxy-Pacific is emerging from the trough
PhillipCapital sees 'more positive outlook' on Koufu despite 'neutral' rating; SAC Capital keeps 'buy' on the counter - THE EDGE SINGAPORE

Broker's Calls

PhillipCapital sees 'more positive outlook' on Koufu despite 'neutral' rating; SAC Capital keeps 'buy' on the counter

In the 1HFY2021 ended June, Koufu reported earnings of $9.9 million, nearly four times higher y-o-y.

Broker's Calls

SAC Capital initiates 'buy' on OTS Holdings as expansion plans expected to bear fruit

Recently listed OTS Holdings gets a 'buy' from SAC Capital.
SAC Capital maintains 'hold' on PropNex but ups target price to $2  - THE EDGE SINGAPORE

Broker's Calls

SAC Capital maintains 'hold' on PropNex but ups target price to $2

The higher TP reflects the strong momentum of the property market that’s expected to continue in the near term.
Hyphens Pharma gets a 'buy' from SAC as it looks to undertake more R&D initiatives - THE EDGE SINGAPORE

Broker's Calls

Hyphens Pharma gets a 'buy' from SAC as it looks to undertake more R&D initiatives

SAC Capital is maintaining its “buy” call and target price of 37 cents on pharmaceutical distributor Hyphens Pharma.
×